We have a robust pipeline of wholly owned and partnered programmes to address a broad spectrum of disease indications.
Our foundation is built on our proprietary soluble TCR bi-specific ImmTAC® platform.
19 February 2021Immunocore’s tebentafusp granted Breakthrough Therapy Designation for unresectable or metastatic uveal melanoma from FDA
16 February 2021Immunocore announces key appointments to management and Board
9 February 2021Immunocore Announces Closing of $312.1 Million Aggregate Financing, Consisting of $297.1 Million Initial Public Offering, Full Exercise of Option to Purchase Additional ADSs and $15.0 Million Concurrent Private Placement